Navigation Links
Nektar Therapeutics to Host Conference Call to Discuss Today's Announcement of a New Partnership for NKTR-118 and NKTR-119
Date:9/21/2009

ing UCB's Cimzia(R), Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia. Nektar has created a robust pipeline of potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. Nektar is currently conducting clinical and preclinical programs in oncology, pain and other therapeutic areas. NKTR-102, PEGylated irinotecan, is currently in Phase 2 clinical studies in ovarian, breast and colorectal cancer. NKTR-105, PEGylated docetaxel, is currently in a Phase 1 clinical study in patients with refractory solid tumors.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Nektar Contacts:

    Jennifer Ruddock
    Nektar Therapeutics
    650-631-4954
    jruddock@nektar.com

    Susan Noonan
    The SAN Group
    212-966-3650
    susan@sanoonan.com


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
2. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
3. Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
4. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
5. Nektar Therapeutics Reports First Quarter 2009 Financial Results
6. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
7. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
8. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
9. Nektar Announces Retirement of Irwin Lerner from Board of Directors
10. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
11. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... 2015 , ... Capital Edge Consulting , a nationwide consulting firm that ... their ranking as one of the top 5000 companies listed on the 2015 ... nation. , “It is truly an honor to be recognized as one of America’s ...
(Date:8/27/2015)... Aug. 27, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... of regenerative medicine, today announced that executives from the ... month of September.  , Pedro ... & Renshaw,s 17th Annual Global Investment Conference on Wednesday, ... St. Regis Hotel in New York City ...
(Date:8/27/2015)... ... August 27, 2015 , ... Inc. Magazine released its annual ... Solutions as number 1,361 in growth for the three years through 2014. Being named ... fastest-growing privately held organizations in the country. , “We are thrilled to make ...
(Date:8/26/2015)... ... August 26, 2015 , ... MediVet Biologics, a ... US laboratory is to open in Manhattan, Kansas in early October, 2015. The ... growth of research and development through collaboration with researchers from Kansas State University’s ...
Breaking Biology Technology:Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3
... is available in Spanish . , U.S. ... site where the virus that causes foot-and-mouth disease (FMD) ... to development of new vaccines to control and potentially ... disease of cloven-hoofed animals that is considered the most ...
... Reportlinker.com announces that a new market research report is ... and Global Markets http://www.reportlinker.com/p0341184/Nanobiotechnology-Applications-and-Global-Markets.html ... is $19.3 billion in 2010 and is growing at ... reach a forecast market size of $29.7 billion by ...
... Inc., a biopharmaceutical company developing novel therapies to treat ... today announced that it has initiated a Phase 1 ... pharmacodynamic profiles of TRX518, a monoclonal antibody designed to ... more effectively attack cancer cells.   The ...
Cached Biology Technology:USDA scientists discover how foot-and-mouth disease virus begins infection in cattle 2Reportlinker Adds Nanobiotechnology: Applications and Global Markets 2Reportlinker Adds Nanobiotechnology: Applications and Global Markets 3Reportlinker Adds Nanobiotechnology: Applications and Global Markets 4Reportlinker Adds Nanobiotechnology: Applications and Global Markets 5Reportlinker Adds Nanobiotechnology: Applications and Global Markets 6Reportlinker Adds Nanobiotechnology: Applications and Global Markets 7Reportlinker Adds Nanobiotechnology: Applications and Global Markets 8Reportlinker Adds Nanobiotechnology: Applications and Global Markets 9Reportlinker Adds Nanobiotechnology: Applications and Global Markets 10Reportlinker Adds Nanobiotechnology: Applications and Global Markets 11Reportlinker Adds Nanobiotechnology: Applications and Global Markets 12Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer 2Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer 3
(Date:8/12/2015)... As the digital payment services ... advanced biometrics technology is accelerating beyond expectations.  While the ... using their credit cards, the digital currency, mobile payment ... services led by companies in the space such as ... (NASDAQ: GOOG ), Apple Inc. (NASDAQ: AAPL ...
(Date:8/10/2015)... TELTOW, Germany , August 10, 2015 ... a world leader in Eye Tracking Technology for more ... OEM Eye Tracking Platform for integration into all consumer ... reference designs for seamless integration of eye tracking into ... HMDs and augmented reality smart glasses. Omnivision,s leading sensor ...
(Date:8/6/2015)... SAN JOSE, Calif. , Aug. 6, 2015 ... the leading developer of human interface solutions, today ... and TouchPad technologies on Windows 10. Microsoft leveraged ... fundamental to the operating system. ... and drivers are fully certified with Microsoft,s Precision ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... tools and techniques for achieving targeted gene delivery and ... the successful application of gene therapy to treat a ... are presented in a series of five provocative articles ... , a peer-reviewed journal published by Mary Ann Liebert, ...
... gold standard for medical-use nanoparticles. A new paper* ... Technology (NIST) and the National Cancer Institute,s Nanotechnology Characterization ... nanoparticle "testbed" to explore how the tiny particles behave ... to characterize nanoparticle formulations to determine just what you,re ...
... freshwater cichlids in the western branch of the East ... thriving ecosystem around Lake Kivu. Natural hazards and ... Rwanda and the Democratic Republic of Congo have compromised ... forests for fuel use and subsistence farming has claimed ...
Cached Biology News:The promise of stem cell-based gene therapy 2Branch offices: New family of gold-based nanoparticles could serve as biomedical 'testbed' 2Benchmarking a slice of Africa; preserving biodiversity through science 2Benchmarking a slice of Africa; preserving biodiversity through science 3Benchmarking a slice of Africa; preserving biodiversity through science 4Benchmarking a slice of Africa; preserving biodiversity through science 5
IHC Polymer Detection Kit (Rabbit DAB)150 slides...
...
Bovine Serum...
Healthy animals 10-32 weeks of age, mixed gender and breed; collected on wet ice following USDA guidelines, using Alsevers solution at 1:2 dilution...
Biology Products: